Arcellx, Inc.
ACLX
Rank in Stocks
#2771
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Share Price
$115.07
Last synced: 2026-05-15
Market Cap
$6.73B
Change (1 day)
0.00%
Change (1 year)
38.04%
Country
US
Trade Arcellx, Inc. (ACLX)
Category
Healthcare
Stock price history for Arcellx, Inc. (ACLX)
Highest end of day price: $115.07 on 2026-05-01
Lowest end of day price: $17.58 on 2022-02-01
Lowest end of day price: $17.58 on 2022-02-01
Stock price history of Arcellx, Inc. from 2022 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 30.35% |
| 2025 | -17.00% |
| 2024 | 52.40% |
| 2023 | 93.55% |
| 2022 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $136.63 | -4.62% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
